Mélanie Rose joins Lovaltech as Director of Innovation
Strengthening our innovation and partnership strategy as LVT-001 enters Phase 2
With a Ph.D. in immunology and oncology, Mélanie has built a career at the intersection of R&D, innovation, and development strategy. In particular, she has contributed to the strategic direction of preclinical and clinical programs, with specific expertise in scientific innovation and intellectual property, which are pivotal to supporting Lovaltech's growth.
Her involvement marks an important milestone in the company’s development. As Lovaltech accelerates its pipeline of intranasal vaccines and expands its platform to new therapeutic applications, Mélanie will help to structure and advance these new programs while strengthening our innovation and intellectual property strategy.
We are delighted to welcome Mélanie as Director of Innovation at this pivotal moment in the company's history, as we prepare to launch Phase II clinical trials for our first nasal vaccine.